Advertisement

The drug, known as muraglitazar, proposed for approval under the brand name Pargluva, was endorsed by a Food and Drug Administration panel last month.

But Cleveland Clinic researchers who analysed data the FDA made public before the panel vote found that patients taking Pargluva faced double the risk of death, heart attack or stroke, compared with those on dummy pills or a similar drug.

The study was published Thursday on the Journal of the American Medical Association Website. – (AP)

Visit our Diabetes Centre for more information.

October 2005
 

Print this article on

Rate this article Poor 1 2 3 4 5 Excellent

JOBS

DELPHI DEVELOPER Gauteng - Johannesburg C++ DEVELOPERS Gauteng SENIOR C++ DEVELOPERS Gauteng - Johannesburg SENIOR .NET DEVELOPERS Gauteng SNR C# / .NET DEVELOPER Gauteng WEB DEVELOPERS Gauteng JAVA / J2EE DEVELOPERS Gauteng C# DEVELOPERS Gauteng - Pretoria Find more jobs Register your CV Post a job